NantOmics: a Leader in Molecular Testing
Precision medicine requires the accurate assessment of molecular alterations within a patient’s tumor.
NantOmics provides solutions that can detect genomic and proteomic alterations in cancer and identify potential treatment options for the personalized management of patients.
NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular testing and the first company to employ an integrated panomic approach to inform personalized treatment options for patients with cancer. Combining DNA sequencing, RNA sequencing, and quantitative proteomics, NantOmics offers extensive testing capabilities that provide a comprehensive molecular profile of a patient’s cancer. Our proprietary analytical platform delivers molecular diagnostic capabilities that provide actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care.
What We Do
NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.
The OncoPlexDx Targeted Proteomic panel provides protein biomarker information for multiple clinically relevant proteins that are the targets for chemotherapy agents and targeted therapies.
Our knowledge database, comprised of hundreds of oncogenes and thousands of cellular pathways, identifies genomic and proteomic alterations with the highest clinical relevance to each patient’s tumor. The alterations are then matched to targeted drugs that might be active against tumors containing the specific alteration.
The GPS Cancer report lists potential treatment options, if available. The report may list FDA-approved targeted drugs with potential for clinical benefit, active clinical trials of drugs with potential for clinical benefit, and/or available drugs to which the cancer may be resistant. The GPS Cancer report does not recommend a treatment plan, and it is the responsibility of the treating physician to develop a personalized treatment plan after discussing the available treatment options and the potential risks associated with each treatment option with the patient.